The resistance to bortezomib (BTZ) in multiple myeloma (MM) is partly due to AKT activation and the upregulation of survivin induced by BTZ, which are the targets of ASA
JIANG-HUA DING,LI-YA YUAN,GUO-AN CHEN
2016-01-01
Abstract:In our previous study, it was found that aspirin (ASA) exerted antimyeloma actions in vivo and in vitro. The resistance to bortezomib (BTZ) in multiple myeloma (MM) is partly due to AKT activation and the upregulation of survivin induced by BTZ, which are the targets of ASA in gastric and ovarian cancer, respectively. Thus, the present study investigated the interaction between ASA and BTZ in MM and further clarified the underlying mechanisms. MM1.S and RPMI-8226 cell lines harboring the Nand K-Ras mutations, respectively, were treated with 2.5 mM ASA, 10 nM BTZ and ASA+BTZ for different durations. The proliferation and apoptosis of the cells were determined, and the underlying mechanisms governing the interaction of ASA and BTZ were examined in the MM cells. Treatment with ASA+BTZ caused higher rates of proliferative inhibition and apoptosis in the MM1.S and RPMI-8226 cells in time-dependent manner, compared with either agent alone. A drug interaction assay revealed the additive effect of ASA and BTZ on the myeloma cells. ASA alone inhibited the levels of phosphorylated AKT (p-AKT) and survivin, whereas BTZ alone augmented the levels of p-AKT and survivin. Of note, ASA markedly decreased the upregulation of p-AKT and survivin induced by BTZ. Treatment with ASA+BTZ significantly suppressed the level of Bcl-2, compared with either agent alone. ASA may potentiate the antimyeloma activity of BTZ against myeloma cells via suppression of AKT phosphorylation, survivin and Bcl-2, indicating the potential of ASA+BTZ in treating MM, particularly for cases of BTZ-refractory/relapsed MM. Introduction Multiple myeloma (MM) is a malignant neoplasia of plasma cells, which accounts for ~10% of all types of hematological cancer. According to the latest statistics, the annual incidence of MM was reported to be 20,450 cases and the mortality rate for MM was 11,090 cases/year in the USA in 2013 (1). In addition, MM has evolved as one of the major diseases affecting the aging population in China (2). At present, MM is the second most prevalent hematological malignancy following non-Hodgkin's lymphoma (2). Even with the introduction of immunmodulators, including thalidomide and lenalidomide, and proteasome inhibitors, including bortezomib (BTZ), over the last decade, the 5-year survival rate of patients in the USA with MM is only 42% (1). In addition, almost all patients with MM undergo relapse and refractory disease, predominantly due to drug resistance (3). Until now, MM remains an incurable disorder among hematological malignancies. Patients with MM are at enhanced risk of thromboembolism due to disease-specific and treatment-specific risk factors, particularly when treated with thalidomide and lenalidomide (4,5). Thus, the prevention of thrombosis has become important in cases of MM. At present, no significant differences have been observed among the use of aspirin (ASA), low-dose warfarin and low-molecular weight heparin in thromboprophylaxis (6). ASA may be the optimum candidate to prevent thromboembolism in patients with MM due to its merits in method of administration, safety and cost without the requirement for regular coagulation monitoring (7). ASA has been widely used for thromboprophylaxis in patients with MM, particularly in cases treated with thalidomide or lenalidomide combinations. An increasing number of studies have demonstrated that ASA possesses antineoplastic actions against a wide range of solid tumor types, including esophageal, breast, lung and gastric cancer, and colon cancer in particular (8-12). Currently, the underlying anticancer mechanisms of ASA have been ascribed to the inhibition of nuclear factor (NF)-kB, and the induction of apoptosis by caspase activation, interruption of extracellular signal-regulated kinase and epidermal growth factor receptor in various types of cancer (13-17). Our previous study found Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT JIANG-HUA DING1, LI-YA YUAN2 and GUO-AN CHEN3 1Hematology and Oncology Department, The No. 171st Hospital of PLA, Jiujiang, Jiangxi 332000; 2Hematology Department, Jiangxi Academy of Medical Science; 3Hematology Department, The 1st Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China Received July 12, 2015; Accepted November 1, 2016 DOI: 10.3892/ol.2016.5472 Correspondence to: Dr Guo-An Chen, Hematology Department, The 1st Affiliated Hospital of Nanchang University, 17 Yongwai Zheng Street, Donghu, Nanchang, Jiangxi 330006, P.R. China E-mail: gachen923@hotmail.com